- Home
- MDXH vs HLVX Comparison
MDXH vs HLVX Comparison
Compare MDXH & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDXH
- HLVX
- Stock Information
- Founded
- MDXH 2003
- HLVX 2020
- Country
- MDXH Belgium
- HLVX United States
- Employees
- MDXH N/A
- HLVX N/A
- Industry
- MDXH
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- MDXH
- HLVX Health Care
- Exchange
- MDXH Nasdaq
- HLVX Nasdaq
- Market Cap
- MDXH 93.1M
- HLVX 87.6M
- IPO Year
- MDXH 2021
- HLVX 2022
- Fundamental
- Price
- MDXH $2.37
- HLVX $1.90
- Analyst Decision
- MDXH Strong Buy
- HLVX Hold
- Analyst Count
- MDXH 2
- HLVX 5
- Target Price
- MDXH $7.00
- HLVX $2.33
- AVG Volume (30 Days)
- MDXH 162.3K
- HLVX 245.3K
- Earning Date
- MDXH 11-06-2024
- HLVX 11-07-2024
- Dividend Yield
- MDXH N/A
- HLVX N/A
- EPS Growth
- MDXH N/A
- HLVX N/A
- EPS
- MDXH N/A
- HLVX N/A
- Revenue
- MDXH $84,708,000.00
- HLVX N/A
- Revenue This Year
- MDXH $27.57
- HLVX N/A
- Revenue Next Year
- MDXH $20.09
- HLVX N/A
- P/E Ratio
- MDXH N/A
- HLVX N/A
- Revenue Growth
- MDXH 33.01
- HLVX N/A
- 52 Week Low
- MDXH $1.55
- HLVX $1.55
- 52 Week High
- MDXH $4.64
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- MDXH 65.97
- HLVX 47.43
- Support Level
- MDXH $2.34
- HLVX $1.95
- Resistance Level
- MDXH $2.52
- HLVX $2.13
- Average True Range (ATR)
- MDXH 0.14
- HLVX 0.07
- MACD
- MDXH 0.05
- HLVX -0.00
- Stochastic Oscillator
- MDXH 77.61
- HLVX 14.81
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.